Last reviewed · How we verify

NCT05825157

Evaluation of Combination Therapy for Upper Extremity Lymphedema

Recruiting now NA Last updated 24 December 2025
What this trial tests

NA trial testing BioBridge in Lymphedema Arm in 60 participants. Currently enrolling.

Timeline
17 November 2023
Primary endpoint
1 January 2027
1 January 2029

Quick facts

Lead sponsorStanford University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date17 November 2023
Primary completion1 January 2027
Estimated completion1 January 2029
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Stanford University

Who can join

Adults 18 to 75, female only, with Lymphedema Arm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigate whether the addition of the Biobridge scaffold to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper extremity. Will Biobridge improve upon the low success rate of the currently practiced surgery by facilitating the lymphatic connections to the transplanted node that are crucial to its viability and function.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lymphedema Arm

Currently open trials in the same condition.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05825157.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing